Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Afrocentric InvestmentJSE:ACT 52 Debt-to-EBITDA is -0.79 as of Dec. 2025. GuruFocus rates JSE:ACT with a GF Score™ of 52/100 and a GF Value™ of R2.07 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Afrocentric Investment ranks worse than 209643.4% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Afrocentric Investment's Debt-to-EBITDA or its related term are showing as below:
JSE:ACT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -11.66 Med: 0.71 Max: 1.73
Current: -10.59
During the past 13 years, the highest Debt-to-EBITDA Ratio of Afrocentric Investment was 1.73. The lowest was -11.66. And the median was 0.71.
JSE:ACT's Debt-to-EBITDA is ranked worse than 100% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs JSE:ACT: -10.59
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Afrocentric Investment Debt-to-EBITDA Related Terms
Afrocentric Investment Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Afrocentric Investment's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:ACT vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Afrocentric Investment's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Afrocentric Investment Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Afrocentric Investment's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Afrocentric Investment's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Afrocentric Investment (JSE:ACT) has a Debt-to-EBITDA of -0.79 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Afrocentric Investment. According to the industry distribution chart, Afrocentric Investment ranks #999999 out of 477 companies in the Healthcare Providers & Services industry.
Is Afrocentric Investment's Debt-to-EBITDA too high?
Afrocentric Investment's current Debt-to-EBITDA is -0.79. Based on the distribution chart, Afrocentric Investment ranks #999999 out of 477 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Afrocentric Investment has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Afrocentric Investment's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Afrocentric Investment ranks #999999 out of 477 companies for Debt-to-EBITDA. This places Afrocentric Investment in the lower half of its industry. The industry median Debt-to-EBITDA is 2.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Afrocentric Investment. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Afrocentric Investment's current Debt-to-EBITDA is -0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Afrocentric Investment stock overvalued right now?
Based on GuruFocus' analysis, Afrocentric Investment (JSE:ACT) is currently considered Possible Value Trap. The stock's GF Value™ is R2.07, compared to a current price of R0.78 — trading 62.3% below its estimated fair value. The current Debt-to-EBITDA is -0.79. Afrocentric Investment's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Afrocentric Investment (JSE:ACT), the current Debt-to-EBITDA is -0.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Afrocentric Investment (JSE:ACT) Overvalued in 2026?
Based on GuruFocus' analysis, Afrocentric Investment stock appears to be undervalued.
The current stock price of R0.78 is trading 62.3% below its estimated GF Value™ of R2.07.
GuruFocus considers Afrocentric Investment to be Possible Value Trap.
Key valuation signals for JSE:ACT:
Debt-to-EBITDA: -0.79
GF Value™: R2.07 vs. price of R0.78 (62.3% below fair value)
No single metric tells the full story. See the JSE:ACT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Afrocentric Investment Corp Ltd is an investment holding company providing specialised services and products to the public and private healthcare sectors. It focuses on making quality healthcare accessible and affordable to members and beneficiaries, with the principal objective of ensuring the delivery of efficient health management services and the distribution of quality products. Its business segments include Healthcare SA, comprising medical scheme administration and health risk management services; Healthcare Retail, comprising pharmaceutical sales and services; Healthcare Africa, comprising healthcare services outside South Africa in Namibia and Mauritius; and IT-related services predominantly within South Africa. It operates across South Africa, Botswana, Mauritius, and Namibia.
52GF Score
Get the complete analysis for JSE:ACT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:ACT has been successfully added to your 
